Novo Nordisk's second late-stage trial data for its obesity drug candidate, CagriSema, failed to meet expectations, leading to significant stock losses. The trial demonstrated weight loss similar to ...
The Danish company said the average weight loss was 15.7% for the new drug, CagriSema. The expectation had been about 25%.
Novo Nordisk stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its next-generation GLP ...
(Reuters) -Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug, Mounjaro, in countries like China, India, ...
Eli Lilly plans to globally launch its diabetes and weight-loss drug, Mounjaro, in countries including China, India, Brazil, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback